CBCN Exam Prep — 9 Week Study Plan

Week 1 — Part 1: Breast Health, Anatomy, and Benign Conditions

Difficulty: Moderate–Heavy

What it covers: Part 1 establishes the anatomic, hormonal, and clinical foundation the rest of the book depends on. You'll learn:

• The functional anatomy of the breast — the terminal ductal lobular unit (TDLU), Cooper's ligaments, the tail of Spence, and the 15–20 lobes that drain via lactiferous ducts to the nipple

• The lymphatic drainage map — axillary node levels I, II, and III relative to the pectoralis minor, plus Rotter's nodes and supraclavicular nodes (involvement = N3, locally advanced)

• Hormonal regulation across the lifecycle — estrogen, progesterone, prolactin, and oxytocin across the menstrual cycle, pregnancy, lactation, and menopause

• Breast development from thelarche through involution using Tanner stages B1–B5

• The systematic clinical breast examination — inspection, vertical-strip palpation with three pressure levels, NAC evaluation, and axillary/supraclavicular/infraclavicular node assessment

• The spectrum of benign breast disease — nonproliferative, proliferative without atypia, and proliferative with atypia

• Cyclic vs. noncyclic mastalgia — and which warrants workup

• Physiologic vs. pathologic nipple discharge — and the most common cause of pathologic discharge

• Peau d'orange as a hallmark sign of inflammatory breast cancer

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System exactly (see the full color key in the front matter).

☐ Lock in the axillary node level map before anything else in this Part. The pectoralis minor is the landmark: Level I is LATERAL to it, Level II is DEEP to it, and Level III is MEDIAL to it (also called infraclavicular). Rotter's nodes sit between pectoralis major and minor. Supraclavicular involvement upstages disease to N3. Approximately 75 percent of breast lymphatic drainage flows to the axillary chain; the rest goes to internal mammary and supraclavicular nodes. This anatomy underlies every staging, surgical, and radiation question later in the book.

☐ Master the functional unit — the terminal ductal lobular unit (TDLU). The TDLU is where most pathology originates (both benign and malignant). Glandular tissue is organized into 15–20 lobes draining via lactiferous ducts to the nipple. Cooper's ligaments suspend the breast from the dermis; when malignancy infiltrates them, the skin tethers and dimples — the anatomic basis for the skin-dimpling sign on exam.

☐ Build a clean reference for hormonal regulation across the lifecycle. Estrogen drives ductal proliferation; progesterone drives lobuloalveolar development; prolactin stimulates milk production; oxytocin triggers milk ejection. Pregnancy produces lactogenesis I (mid-pregnancy) and lactogenesis II (within 72 hours postpartum). At menopause, glandular tissue involutes and is replaced by fat, which is why mammographic density decreases with age. Match these hormonal phases to Tanner stages B1 through B5 so you can quickly orient any age-related clinical question.

☐ Anchor the structure of a complete clinical breast examination (CBE). Visual inspection in multiple positions, vertical-strip palpation of all four quadrants AND the tail of Spence using three levels of pressure (superficial, intermediate, deep), evaluation of the nipple-areolar complex, and assessment of axillary, supraclavicular, and infraclavicular node basins. The CBE complements but does not replace imaging in screening — it is essential for evaluating symptomatic patients.

☐ Master the benign-disease spectrum and its risk implications. Benign breast conditions group into three tiers: nonproliferative lesions (cysts, fibrosis, mild hyperplasia — no increased risk), proliferative lesions WITHOUT atypia (fibroadenoma, intraductal papilloma, sclerosing adenosis — modest risk), and proliferative lesions WITH atypia (atypical ductal or lobular hyperplasia — 4–5x increased risk). Cyclic mastalgia is bilateral, diffuse, varies with the menstrual cycle, and is reassured; noncyclic mastalgia is unilateral and focal and warrants workup. Physiologic nipple discharge is bilateral, multiductal, and non-bloody (often galactorrhea); PATHOLOGIC discharge is unilateral, uniductal, spontaneous, and often bloody — and intraductal papilloma is the most common cause.

☐ Complete the Practice Questions for Part 1 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Breast Health, Anatomy, and Benign Conditions. Main branches: Functional Anatomy (TDLU, Cooper's Ligaments, Tail of Spence) → Lymphatic Drainage & Axillary Node Levels (I, II, III + Rotter's + Supraclavicular) → Hormonal Regulation Across the Lifecycle → Tanner Staging & Breast Development → Clinical Breast Examination → Benign Breast Disease Spectrum (Nonproliferative, Proliferative without Atypia, Proliferative with Atypia) → Mastalgia (Cyclic vs. Noncyclic) → Nipple Discharge (Physiologic vs. Pathologic) → Inflammatory Conditions (Lactational vs. Periductal Mastitis) → Peau d'Orange.

Comparison Charts:

☐ Chart 1 — Axillary Node Levels I vs. II vs. III: Anatomic position relative to pectoralis minor, alternate name (especially Level III/infraclavicular), surgical relevance (SLNB vs. ALND), staging implication, and the supraclavicular upstage to N3.

☐ Chart 2 — Cyclic Mastalgia vs. Noncyclic Mastalgia vs. Extramammary Pain: Laterality, temporal pattern with menstrual cycle, typical age range, location pattern, workup required, and first-line management.

☐ Chart 3 — Physiologic Nipple Discharge vs. Pathologic Nipple Discharge: Laterality, number of ducts, color, presence of blood, association with palpable mass, most common cause, and imaging workup required.

Cornell Notes:

☐ Page 1 — Cue questions: What is the terminal ductal lobular unit, and why is it considered the origin of most benign and malignant breast pathology? How are axillary node levels I, II, and III defined relative to the pectoralis minor, and what is the clinical significance of supraclavicular node involvement?

☐ Page 2 — Cue questions: What are the four essential components of a complete clinical breast exam, and what three levels of pressure are used during vertical-strip palpation? What clinical features distinguish pathologic nipple discharge from physiologic discharge, and what is the most common cause of pathologic discharge?

Week 2 — Part 2: Risk Assessment, Genetics, and Screening

Difficulty: Heavy

What it covers: Part 2 covers the framework for identifying women at elevated breast cancer risk and matching them with appropriate screening, surveillance, and risk-reduction strategies. You'll learn:

• Modifiable vs. non-modifiable risk factors

• The three risk prediction models — Gail (5-year and lifetime, limited in hereditary risk), Tyrer-Cuzick/IBIS (preferred when family history is significant), and BOADICEA/CanRisk (incorporates BRCA1/2 and other genes)

• The 20% lifetime-risk threshold that qualifies a patient for annual breast MRI

• LCIS and atypical ductal hyperplasia as risk MARKERS (not direct precursors) — and the 7–10x and 4–5x risk multipliers they confer

• BRCA1 vs. BRCA2 — chromosome, lifetime risk, typical phenotype (TNBC vs. ER-positive), associated cancers

• Non-BRCA hereditary syndromes — TP53, PTEN, CDH1, PALB2, ATM, CHEK2

• The genetic counseling and cascade testing process, including how to handle a variant of uncertain significance (VUS)

• The four imaging modalities — mammography, digital breast tomosynthesis (DBT), ultrasound, and breast MRI

• BI-RADS assessment categories (0–6) and breast density categories A (fatty) through D (extremely dense)

• NCCN-aligned risk-based screening, chemoprevention (SERMs, AIs), and prophylactic surgical options

• Patient navigation strategies that improve access, adherence, and outcomes

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System exactly (see the full color key in the front matter).

☐ Lock in the 20 percent lifetime-risk threshold before anything else in this Part. A Tyrer-Cuzick or BOADICEA lifetime risk of 20 percent or greater qualifies a woman for HIGH-RISK SCREENING with annual breast MRI in addition to mammography. This threshold is the gateway to enhanced surveillance and is tested directly on the CBCN. Below 20 percent, standard age-based screening applies; above 20 percent, supplemental MRI and consideration of chemoprevention enter the conversation.

☐ Master the three risk prediction models and when each is used. The Gail model uses age, reproductive factors, prior biopsies, and first-degree family history to estimate 5-year and lifetime invasive risk — but it underestimates hereditary risk. Tyrer-Cuzick (IBIS) incorporates EXTENDED family history, hormonal factors, and breast density and is preferred when family history is significant. BOADICEA/CanRisk is the Cambridge model that incorporates BRCA1/2 and other genes alongside family history and lifestyle — used when hereditary risk is a major consideration. Each model answers the SAME question (lifetime risk) but uses different inputs; matching the model to the patient is the tested skill.

☐ Build a clean reference for BRCA1 vs. BRCA2. BRCA1 is on chromosome 17, associated with EARLY-ONSET breast cancer and a strong TRIPLE-NEGATIVE phenotype, plus ovarian cancer. BRCA2 is on chromosome 13, associated with ER-POSITIVE breast cancer, MALE breast cancer, and prostate and pancreatic cancers. Both are high-penetrance (lifetime breast cancer risk 45–85 percent). Three Ashkenazi Jewish founder mutations exist. A variant of uncertain significance (VUS) is NOT actionable on its own — management decisions follow personal and family history, not the VUS itself. Once a familial mutation is identified, CASCADE TESTING of relatives allows efficient identification of at-risk family members.

☐ Anchor LCIS and atypical hyperplasia as RISK MARKERS, not precursors. Lobular carcinoma in situ confers 7–10x increased risk of invasive breast cancer in EITHER breast — it is a marker of generalized risk, not a localized precursor lesion. Atypical ductal hyperplasia (ADH) confers approximately 4–5x increased risk and often upgrades to DCIS or invasive cancer on excision. The CBCN distinction matters because management differs: LCIS triggers heightened surveillance and chemoprevention consideration but not necessarily excision of both breasts; ADH found on core biopsy is typically excised.

☐ Master BI-RADS categories and breast density. BI-RADS is the standardized lexicon used by radiologists to communicate findings and recommend management — categories 0 through 6 plus the density categories A (fatty) through D (extremely dense). Higher density both increases cancer risk AND masks tumors on mammography, which is why dense-breast patients often need supplemental ultrasound or MRI. Digital breast tomosynthesis (DBT, or 3D mammography) reduces recall rates and improves cancer detection, especially in dense breasts.

☐ Complete the Practice Questions for Part 2 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Risk Assessment, Genetics, and Screening. Main branches: Modifiable vs. Non-Modifiable Risk Factors → Risk Prediction Models (Gail, Tyrer-Cuzick/IBIS, BOADICEA/CanRisk) → 20% Lifetime-Risk Threshold → LCIS & Atypical Hyperplasia (Risk Markers) → BRCA1 vs. BRCA2 → Non-BRCA Hereditary Syndromes (TP53, PTEN, CDH1, PALB2, ATM, CHEK2) → Genetic Counseling Process → Cascade Testing → VUS Management → Imaging Modalities (Mammography, DBT, US, MRI) → BI-RADS Categories & Density (A–D) → Chemoprevention (SERMs, AIs) → Risk-Reducing Surgery → Patient Navigation.

Comparison Charts:

☐ Chart 1 — Gail vs. Tyrer-Cuzick vs. BOADICEA: Inputs used, output (5-year and/or lifetime risk), strengths, limitations, preferred clinical scenario, and how each handles strong family history versus hereditary risk.

☐ Chart 2 — BRCA1 vs. BRCA2: Chromosome, lifetime breast cancer risk, lifetime ovarian cancer risk, typical receptor phenotype (TNBC-skewed vs. ER-positive), male breast cancer risk, and other cancers in the syndrome (prostate, pancreatic).

☐ Chart 3 — Standard-Risk Screening vs. High-Risk Screening (≥20% Lifetime): Starting age, mammography frequency, role of supplemental MRI, role of supplemental ultrasound for dense breasts, chemoprevention consideration, and risk-reducing surgery candidacy.

Cornell Notes:

☐ Page 1 — Cue questions: What lifetime risk threshold qualifies a patient for high-risk screening with annual breast MRI, and which two risk models are commonly used to derive that lifetime risk? What are the three categories of benign proliferative disease (with and without atypia), and how does atypical ductal hyperplasia change management when found on core biopsy?

☐ Page 2 — Cue questions: What are the major clinical differences between BRCA1 and BRCA2 hereditary syndromes (typical phenotype, age at onset, associated cancers)? What are the BI-RADS density categories A–D, and why does extremely dense tissue both increase cancer risk and reduce mammographic sensitivity?

Week 3 — Part 3: Diagnosis, Pathology, and Staging

Difficulty: Heavy — High Yield

What it covers: Part 3 is one of the densest and most directly tested sections on the 

CBCN. You'll learn:

• The multi-step model of breast carcinogenesis — the hallmarks of cancer and progression from normal epithelium through atypia to invasive disease

• The three biopsy techniques — fine needle aspiration (22–25 g, cells only), core needle biopsy (14–16 g, current standard), and excisional biopsy (when core isn't feasible)

• Vacuum-assisted biopsy (9–11 g) for stereotactic sampling of microcalcifications

• Image-guided biopsy approaches — stereotactic, ultrasound-guided, MRI-guided — and tumor marker clip placement

• DCIS vs. invasive ductal carcinoma (IDC, 75–80% of invasive cancers) vs. invasive lobular carcinoma (ILC) — including ILC's single-file growth, loss of E-cadherin (CDH1), and tendency toward multifocality and bilaterality

• The Nottingham (modified Scarff-Bloom-Richardson) grading system — Grade 1 (3–5), Grade 2 (6–7), Grade 3 (8–9)

• Biomarker interpretation — ER (≥1% positive per ASCO/CAP), PR, HER2 (0/1+/2+/3+), and Ki-67

• The newer HER2-LOW category (IHC 1+ or 2+/ISH-negative) and its access to T-DXd

• Triple-negative breast cancer (TNBC) — ER-, PR-, and HER2-negative

• The three multigene assays — Oncotype DX (21-gene Recurrence Score), MammaPrint (70-gene), Prosigna (PAM50)

• Lymphovascular invasion and other adverse pathology features

• AJCC 8th edition TNM AND prognostic staging (which incorporates biomarkers and grade)

• Systemic staging imaging — reserved for stage III, suspicious symptoms, or abnormal labs, not asymptomatic early-stage disease

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System exactly (see the full color key in the front matter).

☐ Lock in the receptor framework before anything else in this Part. Every invasive breast cancer is characterized by three biomarkers: estrogen receptor (ER), progesterone receptor (PR), and HER2. Per ASCO/CAP, ER is POSITIVE at 1 percent or more of tumor nuclei staining. HER2 is scored 0, 1+, 2+, or 3+ by IHC: 3+ is positive, 2+ is equivocal (requires ISH/FISH for confirmation), and 0/1+ have traditionally been negative — but the newer HER2-LOW category (IHC 1+ or IHC 2+/ISH-negative) now benefits from antibody-drug conjugates like T-DXd. Triple-negative breast cancer (TNBC) is ER-, PR-, AND HER2-negative — more aggressive, not responsive to endocrine or anti-HER2 therapy. Every treatment decision starts here.

☐ Master the three biopsy techniques and when each is used. Fine needle aspiration (FNA) uses a 22–25 gauge needle and provides cells WITHOUT tissue architecture — mainly used for cysts and selected lymph nodes. CORE NEEDLE BIOPSY (14–16 gauge) preserves tissue architecture and is the CURRENT STANDARD for diagnosing breast lesions. Vacuum-assisted biopsy (typically 9–11 gauge) is used stereotactically for microcalcifications. Excisional biopsy is reserved for situations where core biopsy is not feasible or imaging-pathology concordance fails. A tumor marker clip is placed at the biopsy site so the lesion can be relocalized — especially important if neoadjuvant therapy will follow.

☐ Build a clean reference for DCIS vs. IDC vs. ILC. DCIS is noninvasive malignant proliferation confined to the duct lumen — subtypes include cribriform, papillary, micropapillary, solid, and comedo (with central necrosis), graded as low, intermediate, or high nuclear grade. IDC is the most common invasive breast cancer (75–80 percent), typically "no special type" (NST), arises from the TDLU and breaches the basement membrane. ILC accounts for 10–15 percent of invasive cancers, is characterized by SINGLE-FILE ("Indian filing") cell growth and LOSS OF E-CADHERIN (CDH1), is often MULTIFOCAL, BILATERAL, and ER-POSITIVE — and is notoriously hard to detect on imaging. The CBCN tests these features as recognition patterns.

☐ Anchor Nottingham grade and the multigene assays. The Nottingham (modified Scarff-Bloom-Richardson) grade sums three scores (1–3 each) for tubule formation, nuclear pleomorphism, and mitotic count: total 3–5 = Grade 1 (well-differentiated), 6–7 = Grade 2, 8–9 = Grade 3 (poorly differentiated). Three multigene assays inform chemotherapy decisions in ER-POSITIVE, HER2-NEGATIVE disease: Oncotype DX is a 21-gene assay reporting a Recurrence Score 0–100 (TAILORx, RxPONDER), MammaPrint is a 70-gene assay classifying low vs. high genomic risk (MINDACT), and Prosigna (PAM50) is another option. These assays SUBTRACT chemotherapy from patients who would not benefit — that's their primary clinical value.

☐ Master AJCC 8th edition staging and systemic imaging triggers. The AJCC 8th edition introduced PROGNOSTIC STAGING alongside anatomic TNM — incorporating biomarkers (ER, PR, HER2) and grade into the stage group, because a small triple-negative cancer behaves differently than a small ER-positive Grade 1 cancer. Routine systemic staging imaging (CT chest/abdomen, bone scan, or PET/CT) is NOT recommended for asymptomatic early-stage (I–II) patients — it is reserved for stage III, suspicious symptoms, or abnormal labs. Lymphovascular invasion (LVI) on pathology is an adverse prognostic factor that influences adjuvant therapy decisions.

☐ Complete the Practice Questions for Part 3 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Diagnosis, Pathology, and Staging. Main branches: Carcinogenesis & Hallmarks of Cancer → Biopsy Techniques (FNA, CNB, VAB, Excisional) → Image-Guided Biopsy (Stereotactic, US, MRI) → Tumor Marker Clip & Preoperative Localization → DCIS Subtypes & Grade → IDC vs. ILC (Histology, E-Cadherin, Imaging) → Nottingham Grade → Biomarkers (ER, PR, HER2, Ki-67) → HER2-Low Category → Triple-Negative Breast Cancer → Multigene Assays (Oncotype DX, MammaPrint, Prosigna) → Lymphovascular Invasion → AJCC 8th Edition TNM & Prognostic Staging → Systemic Staging Imaging by Stage.

Comparison Charts:

☐ Chart 1 — FNA vs. Core Needle Biopsy vs. Vacuum-Assisted vs. Excisional Biopsy: Needle gauge or technique, tissue yield (cells vs. architecture), typical indication, image guidance compatibility, and the role of each in current breast diagnostic workflow.

☐ Chart 2 — DCIS vs. IDC vs. ILC: Invasion status, percentage of invasive cancers, typical histologic pattern, E-cadherin status, multifocality and bilaterality rate, imaging detectability, and ER/PR/HER2 typical profile.

☐ Chart 3 — ER/PR/HER2 Subtypes (HR+/HER2-, HR+/HER2+, HR-/HER2+, TNBC, HER2-Low): Definition, frequency, prognosis, first-line systemic approach (endocrine, anti-HER2, chemotherapy, ADC), and key targeted agents available.

☐ Chart 4 — Oncotype DX vs. MammaPrint vs. Prosigna: Number of genes, output format (continuous score vs. binary risk), indication (ER+/HER2- early breast cancer), key supporting trial (TAILORx, RxPONDER, MINDACT), and how each guides chemotherapy decision-making.

Cornell Notes:

☐ Page 1 — Cue questions: What is the ASCO/CAP threshold for ER positivity, and how is HER2 status determined when IHC is 2+ equivocal? What defines the HER2-LOW category, and what therapeutic option does it open up?

☐ Page 2 — Cue questions: What histologic and molecular features distinguish invasive lobular carcinoma from invasive ductal carcinoma, and why is ILC more often multifocal, bilateral, and harder to detect on imaging? What does the Nottingham grading system measure, and what total score ranges correspond to Grades 1, 2, and 3?

☐ Page 3 — Cue questions: Which multigene assay is most commonly used to guide adjuvant chemotherapy decisions in ER-positive, HER2-negative early breast cancer, and what does its Recurrence Score range mean? How does AJCC 8th edition PROGNOSTIC staging differ from anatomic TNM staging, and at what clinical stage is systemic imaging routinely added?

Week 4 — Part 4: Surgical and Radiation Treatment

Difficulty: Heavy — High Yield

What it covers: Part 4 covers the local treatment of breast cancer — the surgical options and the radiation modalities that complete locoregional control. You'll learn:

• Breast-conserving surgery (BCS) vs. mastectomy — oncologic equivalence with adjuvant radiation

• The margin standards — "no ink on tumor" for invasive cancer, ≥2 mm for pure DCIS (per SSO/ASTRO consensus)

• The four mastectomy types — simple (total), modified radical (adds Level I/II ALND), skin-sparing, nipple-sparing

• Risk-reducing mastectomy in high-risk patients (BRCA carriers) — ~90–95% breast cancer risk reduction

• Sentinel lymph node biopsy (SLNB) using blue dye, radioisotope, or both — first draining node, replaces routine ALND in cN0 disease

• The Z0011 criteria — T1–T2 tumors, cN0 axilla, 1–2 positive SLNs, BCS, planned WBI → can safely OMIT ALND

• Axillary lymph node dissection — indications, short- and long-term complications including lymphedema

• Autologous reconstruction — DIEP flap (preserves rectus abdominis vs. older TRAM), latissimus dorsi flap (often with implant)

• Implant-based reconstruction — tissue expander → permanent implant, with acellular dermal matrix (AlloDerm) as a sling

• Whole-breast irradiation — conventional 50 Gy/25 fractions vs. the current standard hypofractionated 40–42.5 Gy/15–16 fractions

• Accelerated partial breast irradiation (APBI) — 1–2 weeks, ASTRO Suitable group eligibility

• Deep inspiration breath hold (DIBH) — gold-standard cardiac sparing for left-sided breast cancer

• Post-mastectomy radiation indications — ≥4 positive nodes, T3/T4 tumors, positive margins, selected 1–3 node-positive cases

• Preoperative and postoperative nursing care

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System exactly (see the full color key in the front matter).

☐ Lock in the margin standards before anything else in this Part. For INVASIVE cancer treated with BCS plus radiation, the standard margin is "NO INK ON TUMOR" per SSO/ASTRO consensus — closer margins do NOT improve local control when radiation follows. For pure DCIS treated with BCS plus radiation, the standard margin is 2 mm OR GREATER. The CBCN tests both numbers directly, and the difference catches students every year. BCS plus whole-breast radiation gives EQUIVALENT survival to mastectomy in early-stage invasive cancer — patient preference and contraindications drive the choice, not oncologic superiority.

☐ Master the Z0011 trial and the SLNB-vs.-ALND decision. Sentinel lymph node biopsy uses blue dye, radioisotope, or both to identify and sample the FIRST draining axillary node — it has largely replaced routine ALND in clinically node-negative early disease. The ACOSOG Z0011 trial showed that patients with T1–T2 tumors, clinically node-NEGATIVE axillas, 1–2 positive sentinel nodes, undergoing BCS PLUS whole-breast radiation can SAFELY OMIT ALND. This is a foundational practice change. ALND is now reserved for clinically positive nodes or selected sentinel-positive cases (3+ positive nodes, mastectomy without radiation planned, or extensive extranodal extension). Know the Z0011 criteria — the CBCN tests them as a complete checklist.

☐ Build a clean reference for the four mastectomy types and risk-reducing mastectomy. Simple (total) mastectomy removes the breast, nipple-areolar complex, and skin — NO axillary dissection. Modified radical adds Level I and II axillary dissection while preserving the pectoral muscles. Skin-sparing preserves the skin envelope for immediate reconstruction (NAC removed). Nipple-sparing preserves both skin and NAC and is appropriate in selected patients with peripheral tumors and adequate skin perfusion. Risk-reducing mastectomy in high-risk patients (e.g., BRCA carriers) reduces breast cancer risk by approximately 90–95 percent.

☐ Anchor reconstruction options. Autologous (flap) reconstruction uses the patient's own tissue — the DIEP flap (deep inferior epigastric perforator) uses lower abdominal skin and fat WITHOUT sacrificing the rectus abdominis muscle (preserves abdominal wall strength vs. the older TRAM flap). The latissimus dorsi flap uses back muscle and is often combined with an implant when volume is inadequate. Implant-based reconstruction commonly proceeds in two stages: tissue expander placed at mastectomy, then exchanged for a permanent implant. Acellular dermal matrix (e.g., AlloDerm) is used as a sling to provide soft tissue coverage in implant-based reconstruction.

☐ Master radiation options. WHOLE-BREAST IRRADIATION (WBI) after BCS: conventional dose is 50 Gy/25 fractions; HYPOFRACTIONATED 40–42.5 Gy/15–16 fractions is the CURRENT STANDARD for most invasive disease (equally effective, fewer fractions, less travel burden). ACCELERATED PARTIAL BREAST IRRADIATION (APBI) delivers radiation to the lumpectomy bed and surrounding tissue over 1–2 weeks in selected low-risk patients meeting ASTRO Suitable criteria. DEEP INSPIRATION BREATH HOLD (DIBH) is the gold-standard cardiac-sparing technique for LEFT-SIDED breast cancer — the inflated lung pushes the heart away from the radiation field. Post-mastectomy radiation is indicated for ≥4 positive nodes, T3/T4 tumors, positive margins, or selected 1–3 positive node cases.

☐ Complete the Practice Questions for Part 4 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Surgical and Radiation Treatment. Main branches: Breast-Conserving Surgery → Margin Standards (No Ink on Tumor — Invasive; ≥2 mm — DCIS) → Four Mastectomy Types (Simple, Modified Radical, Skin-Sparing, Nipple-Sparing) → Risk-Reducing Mastectomy → Sentinel Lymph Node Biopsy → Z0011 Trial Criteria → Axillary Lymph Node Dissection (Indications, Complications, Lymphedema) → Autologous Reconstruction (DIEP, Latissimus Dorsi) → Implant Reconstruction (Tissue Expander, ADM) → Whole-Breast Irradiation (Conventional vs. Hypofractionated) → Accelerated Partial Breast Irradiation (ASTRO Suitable) → Deep Inspiration Breath Hold → Post-Mastectomy Radiation Indications → Perioperative Nursing Care.

Comparison Charts:

☐ Chart 1 — BCS vs. Mastectomy: Oncologic equivalence (with radiation), patient candidacy, contraindications to BCS, margin standards (invasive vs. DCIS), need for adjuvant radiation, and aesthetic and quality-of-life considerations.

☐ Chart 2 — Four Mastectomy Types (Simple/Total vs. Modified Radical vs. Skin-Sparing vs. Nipple-Sparing): What's removed, what's preserved, axillary dissection (yes/no), reconstruction compatibility, and ideal patient selection.

☐ Chart 3 — SLNB vs. ALND (Z0011-Era Decision Framework): Indications, technique, complication rate (especially lymphedema), Z0011 eligibility checklist (T1–T2, cN0, 1–2 SLN+, BCS, WBI planned), and situations where ALND is still required.

☐ Chart 4 — Conventional WBI vs. Hypofractionated WBI vs. APBI: Total dose, number of fractions, treatment duration, eligibility criteria, role of DIBH for left-sided disease, and typical patient profile for APBI per ASTRO Suitable group.

Cornell Notes:

☐ Page 1 — Cue questions: What are the margin standards for invasive breast cancer treated with BCS+radiation versus pure DCIS treated with BCS+radiation, and why does the standard differ? Under what specific clinical conditions (the Z0011 criteria) can a patient with positive sentinel nodes SAFELY omit ALND?

☐ Page 2 — Cue questions: What are the four types of mastectomy, and what is removed and preserved in each? What is the difference between a DIEP flap and the older TRAM flap, and why is DIEP generally preferred when patient anatomy allows?

☐ Page 3 — Cue questions: What is the current standard fractionation for whole-breast irradiation after BCS, and why is deep inspiration breath hold the gold standard for left-sided breast cancer? What are the indications for post-mastectomy radiation therapy?

Week 5 — Part 5: Systemic Therapy and Special Treatment Considerations

Difficulty: Heavy — High Yield

What it covers: Part 5 covers the systemic therapy framework that drives modern breast cancer treatment — and it is one of the most heavily weighted Parts on the CBCN. You'll learn:

• Neoadjuvant vs. adjuvant systemic therapy — goals, indications, and the role of pathologic complete response (pCR)

• The subtype-based therapy framework — HR-positive, HER2-positive, triple-negative, BRCA-mutated

• Endocrine therapy — tamoxifen (SERM, pre- and postmenopausal, CYP2D6 metabolism), aromatase inhibitors (anastrozole, letrozole, exemestane, postmenopausal or with OFS), and ovarian function suppression (goserelin, leuprolide, or surgical oophorectomy)

• The SOFT and TEXT trials supporting OFS in higher-risk premenopausal patients

• The major cytotoxic regimens — AC-T, TC, and TCHP (the standard neoadjuvant HER2+ regimen)

• HER2-targeted antibody therapy — trastuzumab (cornerstone, requires LVEF monitoring), pertuzumab (dual blockade), margetuximab

• The escalation pathways after non-pCR — T-DM1 for residual HER2+ disease (KATHERINE), capecitabine for residual TNBC (CREATE-X)

• Antibody-drug conjugates — T-DM1, T-DXd (active in HER2-positive AND HER2-low; ILD/pneumonitis is the major safety concern), sacituzumab govitecan (Trop-2-directed, metastatic TNBC and HR+/HER2-)

• CDK4/6 inhibitors — palbociclib, ribociclib, abemaciclib (monarchE, NATALEE)

• PARP inhibitors — olaparib, talazoparib for germline BRCA1/2-mutated disease (OlympiA)

• Immune checkpoint inhibitors — pembrolizumab in early TNBC (KEYNOTE-522) and metastatic PD-L1+ TNBC (KEYNOTE-355), with immune-related adverse events

• Inflammatory breast cancer — clinical (not histologic) diagnosis, T4d by definition, neoadjuvant chemo → mastectomy + ALND → radiation

• Paget disease of the breast — eczematous NAC lesion, full-thickness skin biopsy

• Phyllodes tumor — wide local excision, no role for chemo or endocrine therapy

• Fertility preservation and the POSITIVE trial findings

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System exactly (see the full color key in the front matter).

☐ Lock in subtype-based therapy selection before anything else in this Part. Modern breast cancer treatment is BIOLOGY-FIRST, not stage-first. HR-POSITIVE/HER2-NEGATIVE disease gets endocrine therapy as the backbone, plus CDK4/6 inhibitors in metastatic and (now) high-risk early disease. HR-POSITIVE/HER2-POSITIVE gets endocrine therapy PLUS anti-HER2 therapy. HR-NEGATIVE/HER2-POSITIVE gets anti-HER2 therapy plus chemotherapy. TRIPLE-NEGATIVE gets chemotherapy as the backbone (no endocrine, no anti-HER2), with pembrolizumab for high-risk early disease (KEYNOTE-522) and sacituzumab govitecan plus other options for metastatic disease. BRCA-MUTATED disease (any subtype) gains access to PARP inhibitors (olaparib, talazoparib) per OlympiA in high-risk early disease.

☐ Master the endocrine therapy framework. TAMOXIFEN is a SERM used in BOTH pre- and postmenopausal women with ER-positive disease; metabolized by CYP2D6, so paroxetine and fluoxetine are drug-drug interactions to avoid. AROMATASE INHIBITORS (anastrozole, letrozole, exemestane) block PERIPHERAL estrogen production and are used in postmenopausal women OR premenopausal women who are receiving ovarian function suppression. OVARIAN FUNCTION SUPPRESSION (OFS) is achieved with GnRH agonists (goserelin, leuprolide) or surgical bilateral oophorectomy, and is ADDED to endocrine therapy in higher-risk premenopausal patients per the SOFT and TEXT trials.

☐ Build a clean reference for the major cytotoxic regimens. AC-T (doxorubicin + cyclophosphamide followed by a taxane) is the backbone of adjuvant and neoadjuvant chemotherapy. TC (docetaxel + cyclophosphamide) is a shorter, anthracycline-sparing option. TCHP (docetaxel + carboplatin + trastuzumab + pertuzumab) is the standard NEOADJUVANT regimen for HER2-positive disease. PATHOLOGIC COMPLETE RESPONSE (pCR — absence of invasive cancer in breast and lymph nodes after neoadjuvant therapy) strongly predicts improved long-term outcomes, especially in HER2-positive and triple-negative disease — and lack of pCR opens up escalation pathways (T-DM1 after residual HER2+ disease per KATHERINE; capecitabine after residual TNBC per CREATE-X).

☐ Anchor the HER2-targeted hierarchy. TRASTUZUMAB is the cornerstone monoclonal antibody for HER2-positive disease — REQUIRES LVEF MONITORING (cardiotoxicity is the major safety concern, especially in combination with anthracyclines). PERTUZUMAB adds dual HER2 blockade. The antibody-drug conjugates have transformed practice: T-DM1 (trastuzumab emtansine) is the standard for residual HER2-positive disease after neoadjuvant therapy and in metastatic settings; T-DXd (trastuzumab deruxtecan) is active in HER2-positive AND HER2-LOW disease — major safety concern is INTERSTITIAL LUNG DISEASE/PNEUMONITIS. SACITUZUMAB GOVITECAN is a Trop-2-directed ADC used in metastatic triple-negative and HR+/HER2-negative disease — major toxicities are neutropenia and diarrhea.

☐ Master the special clinical entities. INFLAMMATORY BREAST CANCER (IBC) is an aggressive clinical (NOT histologic) diagnosis defined by rapid-onset peau d'orange and erythema covering one-third or more of the breast, often WITHOUT a discrete mass — clinically T4d by definition. Treatment is neoadjuvant chemotherapy first, then mastectomy with ALND, then radiation. PAGET DISEASE of the breast presents as eczematous, scaling, or ulcerated NIPPLE-AREOLAR lesion almost always associated with underlying DCIS or invasive cancer; diagnose with FULL-THICKNESS skin biopsy. PHYLLODES TUMOR is a fibroepithelial tumor (benign, borderline, or malignant) managed with WIDE LOCAL EXCISION with negative margins — chemotherapy and endocrine therapy do NOT play a role. Fertility preservation in young patients includes oocyte/embryo cryopreservation BEFORE chemotherapy and selected interruption of endocrine therapy per the POSITIVE trial.

☐ Complete the Practice Questions for Part 5 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Systemic Therapy and Special Treatment Considerations. Main branches: Neoadjuvant vs. Adjuvant Intent → Pathologic Complete Response (pCR) → Subtype-Based Therapy Framework → Endocrine Therapy (Tamoxifen, AIs, OFS) → Cytotoxic Regimens (AC-T, TC, TCHP) → Anti-HER2 Therapy (Trastuzumab, Pertuzumab, Margetuximab) → LVEF Monitoring → Antibody-Drug Conjugates (T-DM1, T-DXd, Sacituzumab Govitecan) → CDK4/6 Inhibitors → PARP Inhibitors (Germline BRCA) → Immune Checkpoint Inhibitors → Inflammatory Breast Cancer (T4d) → Paget Disease → Phyllodes Tumor → Fertility Preservation & POSITIVE Trial.

Comparison Charts:

☐ Chart 1 — Subtype-Based Systemic Therapy: HR+/HER2- vs. HR+/HER2+ vs. HR-/HER2+ vs. TNBC vs. BRCA-Mutated — first-line approach, role of endocrine therapy, role of chemotherapy, role of targeted therapy (anti-HER2, CDK4/6, PARP, immunotherapy), and key trial supporting use.

☐ Chart 2 — Endocrine Therapy Options (Tamoxifen vs. AI vs. OFS): Mechanism, eligible menopausal status, key drug interactions, dominant side-effect profile (hot flashes, AI-arthralgia, bone loss, VTE risk), and when OFS is added to AI therapy in premenopausal patients.

☐ Chart 3 — HER2-Targeted Agents (Trastuzumab vs. Pertuzumab vs. T-DM1 vs. T-DXd): Mechanism (antibody vs. antibody-drug conjugate), indication (early vs. residual vs. metastatic), HER2-low activity (yes/no), key toxicity (cardiac vs. pneumonitis vs. neutropenia), and required monitoring.

☐ Chart 4 — Special Entities (Inflammatory Breast Cancer vs. Paget Disease vs. 

Phyllodes Tumor): Clinical presentation, diagnostic test, default treatment sequence (neoadjuvant chemo + mastectomy + RT vs. NAC biopsy + mastectomy/BCS vs. wide local excision), and role of systemic therapy (yes/no).

Cornell Notes:

☐ Page 1 — Cue questions: What is the framework for selecting systemic therapy by tumor biology (HR+/HER2-, HER2+, TNBC, BRCA-mutated), and what is the role of pathologic complete response (pCR) in measuring neoadjuvant treatment success? What is the specific significance of NOT achieving pCR — what escalation pathways open up (KATHERINE and CREATE-X)?

☐ Page 2 — Cue questions: What are the three categories of endocrine therapy (SERM, AI, OFS), and which menopausal status fits each? Why is trastuzumab cardiotoxicity such a high-priority monitoring item, and what assessment tool is used (LVEF threshold)?

☐ Page 3 — Cue questions: What is the clinical (not histologic) definition of 

inflammatory breast cancer, and what is the standard treatment sequence? How is phyllodes tumor managed differently from invasive breast cancer, and why is systemic therapy not part of the standard plan?

Week 6 — Part 6: Symptom Management Across Treatment Modalities

Difficulty: Heavy

What it covers: Part 6 covers the symptom management work that defines the daily practice of a CBCN — the postoperative, chemotherapy, radiation, and endocrine therapy side effects you will assess, prevent, and manage every shift. You'll learn:

• Postoperative complications — seroma, hematoma, surgical site infection

• Axillary web syndrome (cording) — palpable cord-like structures 2–8 weeks post-axillary surgery, managed with PT

• Lymphedema — pathophysiology, diagnosis (>2 cm circumferential or >10% volumetric difference), evidence-based prevention, and stepped management (compression, MLD, complete decongestive therapy)

• The PAL trial finding that exercise is PROTECTIVE, not prohibited, after axillary surgery

• Post-mastectomy pain syndrome — chronic neuropathic pain from intercostobrachial nerve injury

• Chemotherapy-induced nausea and vomiting — acute, delayed, anticipatory, breakthrough, and refractory categories

• The emetogenicity-based prophylaxis framework — highly emetogenic (>90%, requires 3- or 4-drug prophylaxis), moderately, low, and minimal

• Myelosuppression and nadir timing (7–14 days post-cycle)

• Febrile neutropenia as an oncologic emergency — ANC <500/µL + temp ≥101°F or sustained ≥100.4°F, antibiotics within 1 hour

• Chemotherapy-induced peripheral neuropathy (CIPN) — sensory > motor > autonomic, from taxanes, platinums, vinca alkaloids

• Chemo brain (cancer-related cognitive impairment)

• Cardiotoxicity — anthracycline (dose-dependent, cumulative ceiling) vs. trastuzumab (reversible, LVEF-monitored every 3 months)

• Radiation dermatitis grading 1–4 and evidence-based skin care

• AI-associated arthralgia — the leading cause of endocrine therapy nonadherence

• Hand-foot syndrome (palmar-plantar erythrodysesthesia), classically with capecitabine

• Treatment-induced menopausal symptoms — vasomotor, vaginal, mood, sleep, bone loss

• Cancer-related fatigue — the most common treatment side effect

• The role of exercise, nutrition, and integrative therapies across the treatment continuum

• Screening for and addressing anxiety, depression, and sleep disturbances

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System exactly (see the full color key in the front matter).

☐ Lock in the febrile neutropenia definition before anything else in this Part. Febrile neutropenia is an ONCOLOGIC EMERGENCY defined as ANC <500/µL (or <1000 with expected drop) PLUS a single oral temperature ≥101°F (38.3°C) OR sustained ≥100.4°F (38.0°C) for over 1 hour. Time to first antibiotic dose is the most critical quality measure — empiric broad-spectrum antibiotics are started WITHIN ONE HOUR of recognition. Myelosuppression nadir typically occurs 7–14 days post-cycle. The CBCN tests both the numerical definition and the urgency of response.

☐ Master CINV prophylaxis by emetogenicity. Chemotherapy-induced nausea and vomiting is classified as acute (within 24 hours), delayed (24–120 hours), anticipatory (before treatment), breakthrough, and refractory — and prophylaxis is REGIMEN-DEPENDENT. HIGHLY EMETOGENIC CHEMOTHERAPY (HEC, >90 percent risk without prophylaxis) — anthracycline + cyclophosphamide is the canonical breast cancer example — requires 3- OR 4-DRUG prophylaxis (5-HT3 antagonist + dexamethasone + NK1 antagonist ± olanzapine). Anticipatory CINV responds best to PREVENTION of poor first-cycle control and to benzodiazepines plus behavioral techniques. The framework is preventive, not reactive.

☐ Build a clean reference for lymphedema prevention and stepped management. Lymphedema is chronic accumulation of protein-rich interstitial fluid in the arm, hand, or chest wall after lymph node disruption AND/OR radiation. Diagnosis combines symptoms with CIRCUMFERENTIAL or VOLUMETRIC measurement (>2 cm difference compared to contralateral, or >10 percent volume increase, is the classic threshold). EVIDENCE-BASED prevention includes early identification, exercise (no longer restricted — exercise is PROTECTIVE per the PAL trial), skin care, and avoidance of unnecessary trauma. Stepped management: compression sleeves and gloves, manual lymphatic drainage, complete decongestive therapy, and surgical options for refractory cases. Axillary web syndrome (CORDING) is a related but distinct entity — palpable, tender, cord-like structures from axilla down the medial arm, appearing 2–8 weeks post-axillary surgery, managed with physical therapy and stretching.

☐ Anchor cardiotoxicity monitoring. Anthracyclines (doxorubicin, epirubicin) cause DOSE-DEPENDENT cardiotoxicity with a CUMULATIVE dose ceiling. Trastuzumab causes REVERSIBLE cardiotoxicity that is monitored by LVEF — for HER2 therapy, cardiotoxicity is defined as LVEF decline ≥10 percentage points to BELOW institutional lower limit of normal OR a symptomatic decline of ≥5 percentage points. Baseline echocardiogram or MUGA is obtained before HER2 therapy and repeated every 3 months during treatment. Holding trastuzumab and reassessing in 4 weeks is the typical response to asymptomatic decline. The CBCN tests both the monitoring schedule and the decision threshold for holding therapy.

☐ Master radiation dermatitis grading and skin care. Radiation dermatitis is graded 1–4: Grade 1 (erythema), Grade 2 (dry desquamation), Grade 3 (moist desquamation), Grade 4 (ulceration/necrosis). Evidence-based skin care during radiation includes gentle washing with fragrance-free cleanser, topical moisturizers, avoidance of strong sun exposure to the treated area, loose clothing, and management of moist desquamation when it develops. AI-ASSOCIATED ARTHRALGIA affects up to half of patients on aromatase inhibitors and is the LEADING CAUSE OF NONADHERENCE — addressing it (NSAIDs, exercise, vitamin D, switching agents, duloxetine per evidence) is critical to maintaining 5+ year endocrine therapy completion.

☐ Complete the Practice Questions for Part 6 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Symptom Management Across Treatment Modalities. Main branches: Postoperative Complications (Seroma, Hematoma, SSI) → Axillary Web Syndrome → Lymphedema (Prevention, Diagnosis, Stepped Management) → Post-Mastectomy Pain Syndrome → CINV (Acute, Delayed, Anticipatory, Breakthrough, Refractory) → Emetogenicity Tiers → Myelosuppression → Febrile Neutropenia (Definition & Urgency) → CIPN (Sensory > Motor > Autonomic) → Chemo Brain → Cardiotoxicity (Anthracyclines vs. HER2) & LVEF Monitoring → Radiation Dermatitis Grading & Skin Care → AI-Associated Arthralgia & Adherence → Hand-Foot Syndrome → Treatment-Induced Menopausal Symptoms → Cancer-Related Fatigue → Exercise, Nutrition & Integrative Therapies.

Comparison Charts:

☐ Chart 1 — Axillary Web Syndrome vs. Lymphedema vs. Post-Mastectomy Pain Syndrome: Onset timing post-surgery, anatomic location, classic exam finding, diagnostic approach, evidence-based first-line management, and rehab/PT role.

☐ Chart 2 — CINV Emetogenicity Tiers (Highly vs. Moderately vs. Low vs. Minimal): Risk percentage without prophylaxis, breast cancer regimens in each tier, prophylactic drug classes (5-HT3, NK1, steroid, olanzapine), and management of breakthrough emesis.

☐ Chart 3 — Anthracycline vs. Trastuzumab Cardiotoxicity: Mechanism, reversibility, dose-dependence, cumulative ceiling, baseline assessment, monitoring schedule, threshold for holding therapy, and response to LVEF decline.

☐ Chart 4 — Radiation Dermatitis Grades 1–4: Clinical appearance, symptoms, evidence-based skin care intervention, when to involve radiation oncology, and when to interrupt treatment.

Cornell Notes:

☐ Page 1 — Cue questions: What is the precise numerical definition of febrile neutropenia (ANC and temperature criteria), and what is the time-to-antibiotic target after recognition? What are the five temporal categories of chemotherapy-induced nausea and vomiting, and how does the emetogenicity tier of the regimen drive prophylaxis?

☐ Page 2 — Cue questions: How is lymphedema diagnosed (symptoms plus what measurement criteria), and what are the evidence-based prevention strategies — and what is the role of exercise after the PAL trial? How is axillary web syndrome (cording) different from lymphedema in onset, anatomy, and treatment?

☐ Page 3 — Cue questions: What is the LVEF threshold that defines trastuzumab cardiotoxicity, and what is the typical monitoring schedule during HER2 therapy? Why is AI-associated arthralgia such a high-priority issue, and what evidence-based interventions help maintain endocrine therapy adherence?

Week 7 — Part 7: Oncologic Emergencies, Survivorship, and Professional Practice

Difficulty: Moderate–Heavy

What it covers: Part 7 covers the highest-acuity events you may encounter, the long arc of survivorship that begins when active treatment ends, and the professional standards that frame everyday CBCN practice. You'll learn:

• Recognition and management of anaphylaxis and hypersensitivity reactions (classically taxanes on the 1st/2nd dose, platinums after multiple cycles)

• Vesicant extravasation as an emergency — stop infusion, leave catheter, aspirate, administer antidote

• The two antidotes — dexrazoxane (IV, within 6 hours, 3 consecutive days) for anthracycline extravasation; hyaluronidase (SC) for vinca alkaloid and selected taxane extravasations

• Febrile neutropenia/sepsis as a time-sensitive medical emergency

• Hypercalcemia of malignancy — IV hydration, bisphosphonates (zoledronic acid), denosumab, calcitonin for rapid effect

• Spinal cord compression — back pain as the cardinal early symptom, emergent MRI of the ENTIRE spine, IV dexamethasone

• Malignant pleural effusion — thoracentesis, pleurodesis, or indwelling pleural catheter

• Cancer-associated VTE — DOACs (apixaban, rivaroxaban, edoxaban) as first-line for most patients; LMWH for high bleeding risk, GI/GU cancers, and selected populations

• Palliative care vs. hospice care — any stage alongside disease-directed therapy vs. ≤6-month prognosis with curative intent forgone for the qualifying condition

• Advance directives and POLST forms

• The Survivorship Care Plan and the IOM 2005 "Lost in Transition" framework

• Evidence-based surveillance — annual mammography, CBE every 6–12 months, NO routine systemic imaging in asymptomatic survivors

• Professional standards from ONS, NCCN, and ASCO

• NAPBC accreditation, clinical trial principles, informed consent requirements

• Adult learning principles and health literacy in patient education

• Quality improvement methodology

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System exactly (see the full color key in the front matter).

☐ Lock in vesicant extravasation management before anything else in this Part. Anthracyclines (doxorubicin, epirubicin) and vinca alkaloids are the major VESICANTS used in breast cancer — drugs capable of causing tissue blistering, necrosis, or ulceration if extravasated. Vesicant extravasation is an EMERGENCY requiring immediate intervention: STOP the infusion, leave the catheter IN PLACE, ASPIRATE residual drug, then administer the appropriate antidote. DEXRAZOXANE (Totect) is the IV antidote for ANTHRACYCLINE extravasation — given WITHIN 6 HOURS, on three consecutive days. HYALURONIDASE is the SUBCUTANEOUS antidote for vinca alkaloid (and selected taxane) extravasations. Time to antidote is the difference between full recovery and surgical reconstruction.

☐ Master the four high-acuity oncologic emergencies. SPINAL CORD COMPRESSION — back pain is the CARDINAL EARLY symptom in 90+ percent of cases (precedes neurologic deficit). Emergent MRI of the ENTIRE SPINE (multiple levels are common) AND IV dexamethasone are the FIRST STEPS, followed by neurosurgical evaluation and radiation. HYPERCALCEMIA OF MALIGNANCY — elevated serum calcium from bone metastases, PTHrP, or tumor cytokines; treated with IV hydration (foundation), bisphosphonates (zoledronic acid) or denosumab, and calcitonin for rapid effect. MALIGNANT PLEURAL EFFUSION — thoracentesis for diagnosis and symptom relief, then pleurodesis or indwelling pleural catheter for definitive management. FEBRILE NEUTROPENIA/SEPSIS — covered in Part 6 but reinforced here as a time-sensitive medical emergency.

☐ Build a clean reference for cancer-associated VTE management. DOACs (apixaban, rivaroxaban, edoxaban) are now FIRST-LINE for most patients with cancer-associated VTE — convenient, oral, no monitoring required, with non-inferior efficacy vs. LMWH. LMWH remains the standard in HIGH BLEEDING RISK patients, certain GI/GU malignancies (where DOACs have higher bleeding risk), and selected populations like severe renal impairment. The CBCN tests this practice shift directly — older "LMWH is always first-line" answers are now wrong.

☐ Anchor the palliative care vs. hospice distinction. PALLIATIVE CARE is specialized care focused on relieving symptoms and improving quality of life at ANY stage of serious illness — DELIVERED ALONGSIDE curative or disease-directed therapy. HOSPICE CARE is comfort-focused care for patients with a prognosis of 6 MONTHS OR LESS if the disease follows its expected course; eligible patients FORGO curative intent for the qualifying condition. Both share symptom-management roots but differ in timing and intent. Early integration of palliative care alongside oncology has been shown to improve quality of life and even survival in some studies — it is no longer reserved for end of life.

☐ Master the survivorship care plan and surveillance schedule. The SURVIVORSHIP CARE PLAN (SCP) — written summary of diagnosis, treatment, surveillance schedule, late-effect monitoring, and healthy-living recommendations — is provided at completion of active treatment per the IOM 2005 "LOST IN TRANSITION" report. Evidence-based BREAST CANCER SURVIVORSHIP surveillance is: ANNUAL mammography, clinical breast exam every 6–12 MONTHS, and NO routine systemic imaging in asymptomatic survivors. The exam tests this directly because clinicians and patients often expect more imaging — but the evidence does not support it.

☐ Complete the Practice Questions for Part 7 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Oncologic Emergencies, Survivorship, and Professional Practice. Main branches: Anaphylaxis & Hypersensitivity Reactions → Vesicant Extravasation (Dexrazoxane, Hyaluronidase) → Spinal Cord Compression (Back Pain → MRI Whole Spine → Dexamethasone) → Hypercalcemia of Malignancy → Malignant Pleural Effusion → Cancer-Associated VTE (DOACs First-Line, LMWH Selected) → Palliative Care vs. Hospice → Advance Directives & POLST → Survivorship Care Plan → Surveillance Schedule (Annual Mammo, CBE, No Routine Imaging) → ONS, NCCN, ASCO Standards → NAPBC Accreditation → Clinical Trial Principles & Informed Consent → Quality Improvement Methodology.

Comparison Charts:

☐ Chart 1 — Vesicant Extravasation Response (Anthracycline vs. Vinca Alkaloid): Stop/aspirate steps, appropriate antidote (dexrazoxane IV vs. hyaluronidase SC), time window (6-hour rule for anthracycline), cold vs. warm compress application, and documentation/escalation pathway.

☐ Chart 2 — Spinal Cord Compression vs. Hypercalcemia of Malignancy vs. Malignant Pleural Effusion: Cardinal early symptom, diagnostic imaging, first medical intervention, definitive treatment, and the impact on overall prognosis.

☐ Chart 3 — Palliative Care vs. Hospice Care: Stage of illness (any vs. terminal), goal (symptom relief alongside Rx vs. comfort-focused), Medicare/insurance eligibility, prognosis criterion (none vs. ≤6 months), and disease-directed therapy allowed (yes vs. forgone for qualifying condition).

Cornell Notes:

☐ Page 1 — Cue questions: What is the immediate response sequence to vesicant 

extravasation (stop, leave catheter, aspirate, antidote), and what are the specific antidotes and time windows for anthracycline versus vinca alkaloid extravasation? What is the cardinal early symptom of spinal cord compression, and what are the first two interventions performed before neurosurgical evaluation?

☐ Page 2 — Cue questions: When does DOAC therapy replace LMWH as first-line for cancer-associated VTE, and in which patient populations is LMWH still preferred? What is the recommended evidence-based surveillance schedule for an asymptomatic breast cancer survivor (mammography frequency, CBE frequency, systemic imaging role) and what is the IOM "Lost in Transition" framework?

Week 8 — Part 8: Psychosocial Dimensions of Care

Difficulty: Moderate

What it covers: Part 8 closes the book with the psychosocial framework that every CBCN must own to deliver whole-person care. You'll learn:

• Cultural humility — distinct from "cultural competence," which implies a finite endpoint

• Health disparities and social determinants of health — including the higher breast cancer mortality among Black women in the U.S. despite lower incidence

• Care of male breast cancer patients (~1% of all breast cancers, often later stage, strongly BRCA2-associated)

• Care of LGBTQ+ patients across the breast cancer trajectory

• The FICA spiritual assessment framework — Faith, Importance, Community, Address in care

• Family dynamics, caregiver burden, and developmentally appropriate support for children of patients

• Disturbed body image after surgery, alopecia, and reconstruction

• Sexuality and reproductive health across the treatment continuum

• The NCCN Distress Thermometer — single-item 0–10 scale plus 39-item problem list; score ≥4 triggers further evaluation ("6th vital sign")

• PHQ-9 (depression screener, with Item 9 specifically screening for suicidal ideation) — 0–4 minimal through 20–27 severe

• GAD-7 (anxiety screener) — 0–4 minimal through 15–21 severe

• Fear of cancer recurrence (FCR), scanxiety, and survivorship guilt

• Adjustment disorder vs. adaptive vs. maladaptive coping

• The HITS screening tool for intimate partner violence — Hurts, Insults, Threatens, Screams; total ≥10 is positive

• The SAFE-T framework for suicide risk assessment — risk factors, protective factors, suicide inquiry, risk level, documentation

• Safety plans (which replace the ineffective "no-suicide contracts")

• Financial toxicity — screening, downstream impact on adherence, and referral pathways

• Triage to mental health, social work, and chaplaincy support

Print: 1 Mind Map, 2 Comparison Charts, 1 Cornell Notes page

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System exactly (see the full color key in the front matter).

☐ Lock in the validated screening tool cutoffs before anything else in this Part. The NCCN DISTRESS THERMOMETER is a single-item 0–10 scale plus a 39-item problem list — a score ≥4 triggers further evaluation; distress is considered the "6th vital sign" in oncology. PHQ-9 is the 9-item depression screener: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe — and ITEM 9 SCREENS FOR SUICIDAL IDEATION (always reviewed individually). GAD-7 is the 7-item anxiety screener: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–21 severe. HITS is the 4-item validated IPV screener (Hurts, Insults, Threatens, Screams) with a positive score ≥10. SAFE-T is the structured suicide risk framework: risk factors, protective factors, suicide inquiry, risk level, documentation.

☐ Master cultural humility and the health disparities framework. CULTURAL HUMILITY is a lifelong commitment to self-reflection, addressing power imbalances, and respectful partnership with patients of all cultural backgrounds — DISTINCT FROM "cultural competence," which implies a finite endpoint. HEALTH DISPARITIES are PREVENTABLE differences in health outcomes between population groups, often driven by social determinants of health. The clearest example in breast cancer: BLACK WOMEN have HIGHER breast cancer MORTALITY despite LOWER incidence than White women in the U.S. — driven by later stage at diagnosis, more aggressive subtypes, and inequities in treatment access. The CBCN tests both the definition and the underlying drivers.

☐ Build a clean reference for the major psychosocial entities in breast cancer survivorship. FEAR OF CANCER RECURRENCE (FCR) is one of the most common and persistent unmet needs in survivors — addressable with structured interventions like ConquerFear and AFTER. SCANXIETY is anxiety around imaging appointments, results, and follow-up scans — peaks in the days before and during the waiting period. SURVIVORSHIP GUILT — distress associated with surviving when others did not — is common in support group and online community settings. ADJUSTMENT DISORDER is emotional or behavioral symptoms in response to an identifiable stressor that resolve within 6 months. ADAPTIVE coping (problem-solving, support-seeking, meaning-making) is associated with better outcomes; MALADAPTIVE coping (denial, substance use, avoidance) is associated with worse outcomes.

☐ Anchor IPV screening and suicide risk assessment. INTIMATE PARTNER VIOLENCE affects approximately 1 in 4 women in their lifetime and cancer treatment can both REVEAL and WORSEN existing IPV. The HITS screening tool asks how often a partner Hurts, Insults, Threatens, and Screams — each item scored 1–5, total ≥10 is positive. Identification is followed by safety planning, documentation, and referral — NOT automatic disclosure or coercion to leave. SAFE-T is the suicide risk framework (Suicide Assessment Five-Step Evaluation and Triage): identify risk factors, identify protective factors, conduct suicide inquiry, assign risk level, document. SAFETY PLANS — written, collaborative documents identifying warning signs, coping strategies, social distractions, people to contact, professional resources, and means-restriction strategies — REPLACE the ineffective "no-suicide contracts" of older practice.

☐ Master financial toxicity and the integrated psychosocial response. FINANCIAL TOXICITY is the negative impact of cancer treatment costs on a patient's quality of life — direct costs (deductibles, copays, drugs), indirect costs (lost work, transportation), and downstream consequences (nonadherence, delay of care). Screening with validated tools (e.g., COST-FACIT) and proactive referral to social work, financial counselors, and patient assistance programs is part of the standard of care.

☐ Complete the Practice Questions for Part 8 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Psychosocial Dimensions of Care. Main branches: Cultural Humility (vs. Cultural Competence) → Health Disparities & Social Determinants → Male Breast Cancer & LGBTQ+ Care → Spiritual Assessment (FICA) → Family Dynamics & Caregiver Burden → Communicating with Children of Patients → Body Image & Sexuality After Treatment → NCCN Distress Thermometer (≥4 Trigger) → PHQ-9 (Item 9 = Suicidal Ideation) → GAD-7 → Fear of Cancer Recurrence & Scanxiety → Survivorship Guilt → Adjustment Disorder → Adaptive vs. Maladaptive Coping → HITS IPV Screening → SAFE-T Suicide Assessment → Safety Plans → Financial Toxicity → Mental Health & Social Work Referral.

Comparison Charts:

☐ Chart 1 — Validated Psychosocial Screening Tools (NCCN Distress Thermometer vs. PHQ-9 vs. GAD-7 vs. HITS): Number of items, target construct, scoring range, clinical action threshold, and the specific item or score that triggers escalation (e.g., PHQ-9 item 9, HITS total ≥10).

☐ Chart 2 — Adaptive vs. Maladaptive Coping: Examples of each, association with psychological and physical outcomes, role of the nurse in supporting adaptive strategies, and the intervention approach when maladaptive patterns dominate (referral, motivational interviewing, mental health collaboration).

Cornell Notes:

☐ Page 1 — Cue questions: What is the difference between cultural humility and cultural competence, and what is the most striking example of a breast cancer health disparity in the U.S.? What are the scoring thresholds and action triggers for the NCCN Distress Thermometer, PHQ-9 (including Item 9), and GAD-7? What is the HITS IPV screening tool, what is its positive threshold, and what is the SAFE-T framework for suicide risk assessment?

Week 9 — Full Review & Exam Simulation

Your final week is not about learning new material — it is about consolidating everything you have built and proving it under exam conditions.

Review Tasks

☐ Re-draw one Mind Map from memory for each Part you feel least confident about. Check it against your original.

☐ Work through your Cornell Notes cue columns for every Part — cover the right-hand notes and answer from memory.

☐ Re-do any quiz bank questions you got wrong across all Parts. Focus on the rationales.

☐ Review the Common Mistakes, Rapid Review, and Self-Assessment Checklist sections for your two or three weakest Parts.

Exam Simulation

☐ Take the full-length CBCN practice exam using the QR code in the back matter of this book. Complete it in one sitting, timed, as close to real exam conditions as possible.

☐ Review your emailed score report. Identify which Parts you missed most and spend your remaining time on those Parts' Rapid Review and clinical scenarios only.